What is this?
cGMP TGA and DSC measure mass change and heat flow under controlled temperature programs to evaluate water/solvent loss, melting, crystallization, glass transition, polymorphic transitions, degradation, and thermal fingerprints.
Interpret thermal events in the context of product performance
Melting, glass transitions, solvent or water loss, degradation, and polymorphic transformations can determine formulation performance, manufacturing robustness, and long-term stability. Triclinic Labs performs differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) using qualified instrumentation, validated or verified methods, and complete cGMP documentation to support development, release testing, stability programs, investigations, and regulatory filings.
Our scientists interpret thermal events alongside sample history and complementary solid-state evidence rather than reporting transition temperatures without context.
Overview of cGMP Thermal Analysis by TGA and DSC Services
When is it used?
Use it when specifications or investigations require thermal identity, moisture/solvent-related behavior, polymorph screening support, amorphous content, stability interpretation, or raw-material qualification.
What are limitations?
Thermal events can overlap, heating can create artifacts, and mass loss does not prove water or solvent identity without KF, MS, FTIR, XRPD, Raman, or other confirmation.
What sample amounts are needed?
Many DSC/TGA runs use small milligram-scale samples, but cGMP method development and validation need replicate material and representative lots.
What techniques compete with it?
KF, DVS, XRPD, Raman/FTIR, microscopy, ssNMR, chromatography, and evolved-gas analysis compete or complement thermal methods.
What does FDA care about?
FDA cares that the method is scientifically justified, specific for the intended attribute in the real matrix, controlled under the quality system, validated or verified where appropriate, data-integrity compliant, and lifecycle managed.
What are common mistakes?
Common mistakes include using exploratory data as release evidence, validating the wrong matrix, ignoring sample preparation, under-documenting controls, relying on one technique when orthogonal evidence is needed, or failing to define the decision before testing.
What is Triclinic's experience with this technique
Triclinic uses cGMP thermal analysis when DSC or TGA results must support regulated decisions about solid form, hydration, solvation, residual volatile content, amorphous/crystalline balance, stability, or material comparability. Real-world applications include release or stability methods, validated or verified thermal procedures, investigation support, and controlled reporting that links thermal events to quality-relevant material attributes.
What changes when the work is cGMP?
Exploratory data can help choose a method, but release or filing-support data require controlled execution. The method must be suitable for the matrix, the quality attribute must be defined, reference standards and controls must be appropriate, and the report or CoA must say only what the data support.
| cGMP concern | Why it matters | Practical control |
|---|---|---|
| Method status | Exploratory, verified compendial, validated custom, and transferred methods have different evidence requirements. | Define status before testing and document any development, verification, validation, or transfer work. |
| Sample matrix | Specificity can fail in real drug product, excipient, talc, low-dose, or complex solid mixtures. | Use representative material, placebo/matrix controls, spike studies, or orthogonal methods where needed. |
| Data integrity | Release or stability results must survive QA review, audit, and regulatory scrutiny. | Use controlled records, system suitability, analyst review, deviations/OOS process, and traceable calculations. |
Specific instruments and capabilities for cGMP Thermal Analysis by TGA and DSC
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this cGMP service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| Thermogravimetric analysis | TA Instruments Q50 and TA Discovery 5500 TGA systems | Mass-loss, moisture/volatile content, decomposition, oxidative stability, and residue/composition analysis. |
| TGA-IR evolved-gas analysis | TA TGA with Thermo Nicolet 6700 IR interface; DTGS detector; gas cell to 250 °C; transfer line to 225 °C; nitrogen or helium purge | Evolved-gas identification, volatile/decomposition-product interpretation, and coupling of weight-loss events to IR spectra. |
| TGA software | Thermal Advantage Release 5.5.3; TRIOS v.4.3.1.39215 for Discovery 5500 workflows | Thermal-method acquisition, processing, reporting, and data review. |
| Differential scanning calorimetry | TA Instruments Q2000 and Q2500 Discovery DSC systems | Melting, crystallization, glass transition, heat capacity, compatibility, and transition-enthalpy measurements. |
| Modulated DSC capability | TA Discovery DSC configuration with modulated DSC support | Separation of overlapping reversible/non-reversible events and improved amorphous-content / glass-transition interpretation. |
| DSC software | Thermal Advantage Software v.5.5.3 | DSC acquisition and thermal-event analysis for cGMP and non-GMP workflows. |
Kofler Hot-Stage Microscopy and Thermal Event Interpretation
This example shows why visual thermal evidence can be useful when DSC or TGA events overlap or require interpretation. TGA, TG-IR, DSC, microcalorimetry, and hot-stage microscopy can support moisture/volatile loss, degradation, glass transition, crystallization, melting, oxidative stability, and phase-transition questions. For cGMP methods, event assignment must be tied to the intended quality attribute and supported by orthogonal methods where form identity matters.
Technical Resources and Publications
These examples cite Triclinic source documents, regulatory guidances, or literature relevant to this cGMP service. Download buttons are positioned at the bottom-left of each example.
Amorphous Content Quantitation via mDSC
Author: Triclinic Labs
Publication date: 2025
Abstract: This application note uses modulated DSC to quantify amorphous content in crystalline API by heat-capacity change at the glass transition, supporting thermal-method use for cGMP-capable material control strategies.
ICH Q2(R2) Validation of Analytical Procedures and ICH Q14 Analytical Procedure Development
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: These harmonized guidances describe validation and development principles for analytical procedures used to assess drug-substance and drug-product quality. They anchor expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence in cGMP work.
Related cGMP services
NMR
Use cGMP NMR for identity, purity, qNMR, reference-material verification, method development, validation, and release testing.
View serviceXRPD
Use cGMP XRPD for solid-form identification, polymorph or phase quantitation, crystallinity, method validation, release, and stability support.
View serviceParticle Size Analysis
Develop, validate, verify, and transfer wet or dry particle-size methods for release specifications and quality decisions.
View serviceRaman / FTIR
Use cGMP Raman and FTIR for raw-material ID, solid-form differentiation, mapping, contaminant ID, and validated spectroscopic methods.
View serviceMorphology
Use cGMP microscopy and particle morphology evidence for identification, particle shape, foreign-material work, and regulated investigations.
View serviceRelease Testing Services
Use verified or validated methods to support batch disposition, CoA issuance, stability testing, and regulatory documentation.
View serviceCommon questions
When should DSC be selected instead of TGA?
DSC should be selected when the primary question concerns heat-flow events such as melting, glass transition, crystallization, enthalpy relaxation, or a solid-solid transformation. TGA should be selected when the question concerns mass change, including water or solvent loss, volatilization, oxidation, sublimation, or decomposition. Because many pharmaceutical events involve both heat flow and mass loss, DSC and TGA are frequently complementary.
How can a DSC thermogram be interpreted?
Evaluate the direction, onset, peak temperature, breadth, enthalpy, reversibility, and sequence of events in relation to composition, solid form, thermal history, pan configuration, atmosphere, and heating rate. Endotherms may indicate melting, dehydration, desolvation, or solid-state transitions; exotherms may indicate crystallization, conversion, oxidation, reaction, or degradation. Assignments may require TGA, XRPD, microscopy, spectroscopy, or chemical analysis.
Can DSC independently identify pharmaceutical polymorphs?
No. DSC can show different thermal behaviors, but it cannot independently establish polymorphic identity because melting, recrystallization, desolvation, decomposition, impurities, particle size, and experimental conditions can produce similar or overlapping events. XRPD is generally the primary method for distinguishing crystalline phases, while DSC provides complementary information about transition temperatures, melting behavior, enthalpy, and kinetic relationships.
How can thermal degradation be distinguished from melting?
Determine whether the event involves chemical change, mass loss, gas evolution, discoloration, irreversible residue, or altered composition. Melting normally represents loss of crystalline order without changing molecular identity, whereas degradation produces new chemical species. DSC alone may not distinguish them. TGA, simultaneous DSC-TGA, hot-stage microscopy, evolved-gas analysis, chromatography, spectroscopy, and heated-residue analysis may be required.
Why do multiple thermal events appear in DSC data?
Pharmaceutical materials can undergo several sequential or overlapping processes during heating, including glass transition, enthalpy relaxation, dehydration, desolvation, solid-solid conversion, crystallization, eutectic melting, melting, oxidation, reaction, and decomposition. Multiple events do not automatically prove multiple polymorphs or components. Interpretation requires correlation with TGA, XRPD, microscopy, spectroscopy, chemical analysis, pan conditions, heating rate, and sample history.
When should modulated DSC be used?
Use modulated DSC when conventional DSC cannot adequately separate overlapping events or when a weak glass transition must be distinguished from enthalpy relaxation, crystallization, evaporation, curing, or other kinetic processes. It is especially useful for amorphous materials, polymers, solid dispersions, partially crystalline samples, and complex formulations. TGA, XRPD, microscopy, or chemical analysis may still be needed when phase identity or degradation is uncertain.
How can TGA identify volatile components and solvates?
TGA detects and quantifies volatile components by measuring percentage mass loss as temperature or time increases. Stepwise losses may support the presence of moisture, hydrate water, residual or channel solvent, stoichiometric solvates, volatile excipients, subliming material, or degradation products. TGA does not identify the volatile species or prove lattice incorporation, so confirmation may require Karl Fischer titration, gas chromatography, evolved-gas analysis, XRPD, DVS, spectroscopy, or controlled-humidity studies.
How can thermal analysis support excipient compatibility studies?
DSC and TGA can screen API-excipient mixtures for changes in melting, glass transition, crystallization, volatile loss, reaction enthalpy, and degradation behavior. Peak shifts, broadening, or disappearance do not independently prove incompatibility. Results must be compared with the individual components and interpreted in light of mixture composition, preparation, pan conditions, and chemical stability data. HPLC, XRPD, FTIR, Raman, microscopy, moisture analysis, or stressed-storage studies may be needed for confirmation.
Discuss cGMP testing requirements
Send the sample type, intended use of the data, method or monograph if available, specification, matrix, timeline, and whether the work is exploratory, cGMP, validation, transfer, stability, release, or investigation support.